USANA Health Sciences (NYSE:USNA) Releases Earnings Results, Misses Expectations By $0.62 EPS

Key Points

• USANA Health Sciences reported earnings of ($0.15) per share for the quarter, significantly missing analyst expectations of $0.47 by $0.62.
• The company's stock declined by 1.0% to $20.82, with a market capitalization of $380.33 million and a P/E ratio of 11.56.
• Several brokerages have downgraded USANA Health Sciences from a "buy" rating to "hold," with a current consensus rating of "Reduce" and an average price target of $36.00.

USANA Health Sciences (NYSE:USNA - Get Free Report) issued its earnings results on Wednesday. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.47 by ($0.62), Zacks reports. USANA Health Sciences had a return on equity of 9.48% and a net margin of 3.79%.

USANA Health Sciences Stock Down 1.0%

USANA Health Sciences stock traded down $0.22 during mid-day trading on Wednesday, hitting $20.82. 280,329 shares of the company's stock were exchanged, compared to its average volume of 175,027. The company's 50 day simple moving average is $28.47 and its 200-day simple moving average is $29.01. USANA Health Sciences has a fifty-two week low of $19.88 and a fifty-two week high of $41.83. The firm has a market capitalization of $380.33 million, a P/E ratio of 11.56, a PEG ratio of 1.01 and a beta of 0.61.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on USNA. Wall Street Zen downgraded USANA Health Sciences from a "buy" rating to a "hold" rating in a report on Saturday, October 11th. Zacks Research cut USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a research report on Monday, September 22nd. Finally, Weiss Ratings reissued a "sell (d+)" rating on shares of USANA Health Sciences in a research report on Wednesday, October 8th. Three analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, USANA Health Sciences currently has a consensus rating of "Reduce" and an average target price of $36.00.

Insider Activity

In other USANA Health Sciences news, Director Gilbert A. Fuller sold 1,058 shares of USANA Health Sciences stock in a transaction dated Thursday, August 7th. The stock was sold at an average price of $29.10, for a total value of $30,787.80. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider David Mulham Mulham sold 3,515 shares of the firm's stock in a transaction dated Wednesday, July 30th. The shares were sold at an average price of $30.26, for a total value of $106,363.90. Following the completion of the transaction, the insider owned 9,260 shares of the company's stock, valued at $280,207.60. The trade was a 27.51% decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.63% of the company's stock.

Institutional Investors Weigh In On USANA Health Sciences

Hedge funds and other institutional investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC raised its position in USANA Health Sciences by 382.5% during the second quarter. Tower Research Capital LLC TRC now owns 2,398 shares of the company's stock valued at $73,000 after purchasing an additional 1,901 shares in the last quarter. Quantbot Technologies LP grew its stake in shares of USANA Health Sciences by 19.5% in the second quarter. Quantbot Technologies LP now owns 3,957 shares of the company's stock worth $121,000 after purchasing an additional 646 shares during the last quarter. Caxton Associates LLP bought a new stake in shares of USANA Health Sciences in the second quarter worth $202,000. State of Wyoming boosted its position in USANA Health Sciences by 48.1% during the second quarter. State of Wyoming now owns 7,725 shares of the company's stock valued at $236,000 after acquiring an additional 2,509 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its position in USANA Health Sciences by 969.8% during the second quarter. BNP Paribas Financial Markets now owns 9,243 shares of the company's stock valued at $282,000 after acquiring an additional 8,379 shares during the last quarter. 54.25% of the stock is currently owned by institutional investors and hedge funds.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.